ScoreWhy is Orchid Pharma Ltd ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 14.73 times
- Poor long term growth as Operating profit has grown by an annual rate 15.60% of over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 14.73 times
- The company has been able to generate a Return on Equity (avg) of 4.82% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Operating profit has grown by an annual rate 15.60% of over the last 5 years
3
Flat results in Jun 26
- PAT(9M) At Rs 23.78 cr has Grown at -36.38%
- ROCE(HY) Lowest at 1.27%
- DEBT-EQUITY RATIO(HY) Highest at 0.28 times
4
With ROCE of -0.9, it has a Very Expensive valuation with a 4 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 37.10%, its profits have fallen by -72.1%
5
High Institutional Holdings at 21.55%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Orchid Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Orchid Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Orchid Pharma
37.21%
0.87
42.91%
Sensex
-9.4%
-0.70
13.49%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
20.46%
EBIT Growth (5y)
15.60%
EBIT to Interest (avg)
2.09
Debt to EBITDA (avg)
5.73
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
0.59
Tax Ratio
0.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
21.55%
ROCE (avg)
1.37%
ROE (avg)
4.82%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
332
Industry P/E
37
Price to Book Value
4.65
EV to EBIT
1402.88
EV to EBITDA
141.72
EV to Capital Employed
4.00
EV to Sales
5.84
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.94%
ROE (Latest)
0.71%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
NET SALES(Latest six months)
At Rs 672.50 cr has Grown at 34.32%
PAT(Q)
At Rs 3.22 cr has Grown at 40.8% (vs previous 4Q average
-9What is not working for the Company
PAT(9M)
At Rs 23.78 cr has Grown at -36.38%
ROCE(HY)
Lowest at 1.27%
DEBT-EQUITY RATIO(HY)
Highest at 0.28 times
NON-OPERATING INCOME(Q)
is 69.06 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Orchid Pharma
Profit After Tax (PAT) - Quarterly
At Rs 3.22 cr has Grown at 40.8% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 2.29 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Latest six months
At Rs 672.50 cr has Grown at 34.32%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Orchid Pharma
Debt-Equity Ratio - Half Yearly
Highest at 0.28 times and Grown
each half year in the last five half yearly periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Non Operating Income - Quarterly
is 69.06 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
